Sulforaphane
1. Identity
Chemical Name and Classification
Sulforaphane (SFN), systematically named 1-isothiocyanato-4-(methylsulfinyl)butane, belongs to the isothiocyanate class of phytochemicals. Its molecular formula is C6H11NOS2, and it is the biologically active isothiocyanate produced by the metabolism of glucoraphanin by the enzyme myrosinase. In its liquid state, sulforaphane has a molecular weight of approximately 177.28 g/mol, and it typically melts around 74.6 °C, though its melting point can vary between 58.6 °C and 91.2 °C.
Botanical Sources
Sulforaphane can be extracted from the plants of the genus Brassica. However, broccoli sprouts are the chief source of sulforaphane and are 20 to 50 times richer than mature broccoli, containing 1,153 mg/100 g. Glucoraphanin, the glucosinolate precursor of sulforaphane, is found in cruciferous vegetables such as broccoli, cabbage, cauliflower, and kale. Additional sources within the Brassicaceae family include Brussels sprouts, horseradish, parsnip, radish, wasabi, watercress, and white mustard.
The Glucoraphanin–Sulforaphane Precursor Relationship
All glucosinolates are composed of a basic structure consisting of a β-D-thioglucose group, a sulfonated oxime group, and an amino acid-derived side chain. Glucosinolates are activated by enzyme-dependent hydrolysis to their respective isothiocyanates. The enzyme myrosinase is naturally present in the plant and is released from plant vacuoles after mechanical stress — for example, during cutting or chewing. Glucoraphanin is derived from dihomomethionine, which is methionine chain-elongated twice. In plants, sulforaphane deters insect predators and acts as a selective antibiotic.
Physical Properties and Stability
Sulforaphane exhibits weak solubility in water but demonstrates solubility in organic solvents like methanol, ethanol, dimethyl sulfoxide, and ethyl acetate. It typically appears as a yellow or colorless liquid at room temperature, and the molecule is susceptible to disintegration at high temperatures, given its relatively low melting point of 74.6°C.
Common Forms and Preparations
In human administration, sulforaphane can be delivered either directly in its active form or as glucoraphanin (GRP). Commercial preparations include broccoli sprout powders and extracts, glucoraphanin-standardized tablets or capsules (where myrosinase converts the precursor to active sulforaphane in the gut), and purified sulforaphane. In preferred embodiments, the sulforaphane precursor glucoraphanin and the enzyme myrosinase are obtained from broccoli, broccoli sprouts, or broccoli seeds, and can be obtained from the same source or from different sources — including as an extract or powder from broccoli seed or sprout.
2. Traditional and Historical Use
Sulforaphane as an isolated chemical compound has no traditional history of use — it was not identified until the modern era. What does have a documented traditional history is the broad class of cruciferous vegetables from which sulforaphane is derived.
Since the period of the Roman Empire, Brassicas have been considered very valuable vegetables, and in the mid-18th century in England, broccoli was first introduced as "Italian asparagus," while in the 1920s it first became popular in the USA.
Isothiocyanates, especially sulforaphane, have been used as a medicine in China for thousands of years, with references to cruciferous vegetables appearing in traditional Chinese medical contexts. However, the specific attribution of sulforaphane as the active agent in these traditions is a retroactive scientific interpretation, not an explicit claim from within those traditions themselves.
Before the modern scientific discovery of sulforaphane, traditional cuisines worldwide treasured cruciferous vegetables for their bold flavors and digestive benefits. In Europe, fermented cabbage (sauerkraut) was consumed in winter to support gut health, while in East Asia, mustard greens and daikon radish served as digestive aids. In classical Ayurvedic texts, there is no direct mention of sulforaphane; instead, cabbage-family vegetables are loosely categorized by taste (rasa) and post-digestive effect (vipaka).
In the middle of the last century, sulforaphane was described as an antibiotic and was isolated from red cabbage and from hoary cress, a weed in rangelands of the western United States. It was first synthesized and first isolated from broccoli by Talalay and Zhang. The multiple actions of sulforaphane in humans have been widely studied since 1992, when Talalay and associates discovered its action as an inducer of detoxifying enzyme systems.
3. Key Constituents and Active Compounds
Sulforaphane Within the Isothiocyanate Family
Sulforaphane is a compound within the isothiocyanate (ITC) group of organosulfur compounds. ITCs are hydrolysis products of glucosinolates, secondary plant metabolites found in high concentrations in Brassica vegetables. ITCs are synthesized and stored as glucosinolates in plants and are released when damage to plant tissues occurs. The most characterized ITC compound is sulforaphane, the hydrolysis product of glucoraphanin, generally found in high concentrations in broccoli.
Glucoraphanin — the Precursor
All glucosinolates are composed of a basic structure consisting of a β-D-thioglucose group, a sulfonated oxime group, and an amino acid-derived side chain. Glucoraphanin is converted to sulforaphane by the enzyme myrosinase. The stereochemistry is set when an oxygen atom is added to 4-methylthiobutylglucosinolate by a flavin monooxygenase.
Bioavailability
Upon oral administration, sulforaphane is often absorbed from the intestine, displaying lower bioavailability, a shorter half-life, and a significant first-pass effect. Studies in rat models found that sulforaphane was very well and rapidly absorbed and displayed an absolute bioavailability of 82%, which decreased at higher doses, indicating a dose-dependent pharmacokinetic behaviour; it is concluded that orally administered sulforaphane is rapidly absorbed, achieving high absolute bioavailability at low dietary doses, but dose-dependent pharmacokinetics was evident, with bioavailability decreasing with increasing dose. When glucoraphanin rather than active sulforaphane is consumed, intestinal bacterial myrosinase activity plays a key role in liberation of the active compound in the colon.
4. Established Mechanisms of Action
4.1 The KEAP1–NRF2 Pathway: The Validated Primary Target
Many putative cellular targets are affected by sulforaphane, although only one — KEAP1-NRF2 signaling — can be considered a validated target. The transcription factor NRF2 is a master regulator of cell survival responses to endogenous and exogenous stressors.
Under basal conditions, Nrf2 binds to its repressor Keap1 in the cytoplasm and subsequently undergoes proteasomal degradation via ubiquitination. Under oxidative stress, Nrf2 dissociates from Keap1 and then translocates into the nucleus, where it binds with the small protein Maf at ARE sequences in the promoter regions of target genes. This drives the expression of several cytoprotective genes, such as heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase-1 (NQO1), and superoxide dismutase (SOD).
In mammals, sulforaphane can upregulate stress-induced signaling pathways, including the NRF2 transcriptional pathway, which is conserved across mammalian species. Sulforaphane activates NRF2 transcriptional machinery to upregulate the expression of antioxidant genes and phase II detoxifying enzymes.
The induction of phase II enzymes by sulforaphane is associated with the modification of the thiol group of Keap1, leading to the disruption of Nrf2-Keap1 interactions and increased nuclear translocation of the transcription factor Nrf2. Once free from Keap1, Nrf2 dimerizes with small Maf proteins and binds to antioxidant/electrophile response elements (ARE/EpRE) found in the promoter regions of numerous phase II/antioxidant genes.
4.2 Phase I and Phase II Enzyme Modulation
Sulforaphane is extensively metabolized and can therefore compete with other substrates of Phase I, II, and III enzymes and transporters. In addition, it has an unusually high potency as an inducer of phase II enzymes and regulates the expression and function of different cytochrome P-450 genes. Sulforaphane has also shown chemoprotective properties through inhibiting phase I metabolizing enzymes, modulating phase II xenobiotic-metabolizing enzymes, and targeting cancer stem cells.
4.3 Epigenetic Mechanisms
Accumulating evidence supports that epigenetic modification is an important factor in carcinogenesis and cancer progression, as epigenetic alterations often contribute to the inhibition of tumor-suppressor genes and the activation of oncogenes. Studies on the mechanisms underlying the anticancer effects of sulforaphane have shown that it can reverse such epigenetic alterations in cancers by targeting DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and noncoding RNAs.
A noteworthy aspect of sulforaphane's mechanism involves its capacity as a histone deacetylase (HDAC) inhibitor.
4.4 Anti-Inflammatory Signaling
It has been reported that sulforaphane activates Nrf2 activity in peritoneal macrophages and exerts anti-inflammatory effects via the inhibition of TNF-α, IL-1β, COX-2, and iNOS expression in murine models.
4.5 Cell Cycle and Apoptosis
Sulforaphane exerts its anticancer effects by modulating key signaling pathways and genes involved in the induction of apoptosis, cell cycle arrest, and inhibition of angiogenesis. Cell cycle analysis showed that sulforaphane caused G2/M phase arrest leading to inhibition of tumor proliferation/growth, which was associated with downregulation of cyclin B1 and cyclin D1 genes, as well as increased protein levels of p21WAF1/CIP1 (an inhibitor of cyclin-dependent kinases).
4.6 Hormesis
Sulforaphane induces hormetic dose responses through upregulation of the Nrf2/ARE pathway. This biphasic response is well integrated, concentration dependent, and specific to targeted cell types. The hormetic response of sulforaphane can decrease the incidence and severity of various human-related pathologies, and it has also been found to be involved in the enhancement of stem cell proliferation.
5. Scientific Evidence by Area of Use
5.1 Cancer Prevention and Treatment
Overview of the evidence base: A 2025 review evaluated clinical trials registered on ClinicalTrials.gov focusing on those using sulforaphane or broccoli-derived extracts; 84 trials were identified, of which 39 have been published. A systematic review following Cochrane guidelines conducted in 2023 reported that eight randomized controlled trials (RCTs) investigating the efficacy and safety of sulforaphane in prostate cancer, breast cancer, pancreatic cancer, and melanoma were identified; dosing regimens were variable and inconsistent across the studies.
Prostate cancer: Sulforaphane treatment led to statistically significant alterations in several vital genes and histological biomarkers across studies. However, it did not impact some other key genes. In cancer patients, sulforaphane showed promise in early-stage prostate and breast cancer, particularly in GSTM1-positive individuals, but had limited effects in advanced cases.
Breast cancer: Most of the available evidence on sulforaphane's impact and safety in breast cancer management is from cell culture studies and animal models; the available systematic review evidence consolidates data to determine whether empirical human studies are needed.
Overall evidence strength for cancer: To date, the use of sulforaphane for the treatment and prevention of different types of cancers is supported and widely investigated in preclinical, clinical, and epidemiological studies. It is unclear how significant the added benefits of sulforaphane are in patients with a confirmed cancer diagnosis, and whether it should be recommended as an additional intervention in cancer treatment guidelines when supplied from dietary sources or as an extract. Approximately 50% of completed trials remain unpublished, raising concerns about publication bias.
Epidemiological observations: Numerous studies have suggested that high dietary intake of cruciferous vegetables is correlated with a low risk of cancer. Observational studies have been conducted to determine if consumption of cruciferous vegetables affects cancer risk in humans, but there is insufficient clinical evidence to indicate that consuming glucoraphanin and other isothiocyanates in cruciferous vegetables is beneficial, according to a 2017 review.
5.2 Environmental Detoxification
A randomized, double-blinded, placebo-controlled clinical trial evaluated whether intake of sulforaphane enhances the detoxification metabolism of environmental carcinogens and toxicants such as benzene and acrolein in 283 subjects (89% non-smokers) exposed to substantial levels of airborne pollutants in China. Intake of a broccoli sprout-derived beverage providing daily doses of 600 micromole glucoraphanin and 40 micromole sulforaphane for 12 weeks significantly increased the urinary excretion of detoxification mercapturic acids formed from benzene by 61% (P<0.001) and acrolein by 23% (P=0.01). This study provided strong evidence that broccoli sprout beverage can modulate the disposition of environmental carcinogens and toxins.
5.3 Type 2 Diabetes and Glucose Metabolism
Analysis of coexpression networks and genetic data to identify a disease signature for type 2 diabetes in liver tissue identified sulforaphane as a compound that may reverse the disease signature. Sulforaphane suppressed glucose production from hepatic cells by nuclear translocation of NRF2 and decreased expression of key enzymes in gluconeogenesis. Moreover, sulforaphane reversed the disease signature in the livers from diabetic animals and attenuated exaggerated glucose production and glucose intolerance by a magnitude similar to that of metformin.
In obese patients with dysregulated type 2 diabetes, highly concentrated sulforaphane may significantly lower blood sugar levels, improving fasting glucose and glycated hemoglobin. However, few studies refer to the direct application of sulforaphane in clinical trials; most studies mainly focus on the evaluation of the clinical effects of precursors such as glucoraphanin, or on extracts rich in sulforaphane.
Metabolic disease studies revealed glycaemic control improvements in type 2 diabetes but no benefits for hypertension. Clinical evidence suggests that foods rich in sulforaphane, like broccoli, can improve the metabolic status and lower cardiovascular disease risk by reducing biomarkers of oxidative stress and inflammation in patients with type 2 diabetes.
Evidence strength: Preliminary to moderate. Most mechanistic evidence is preclinical. A small number of human clinical studies show promising signals for glycaemic control, but robust large-scale RCTs directly using isolated sulforaphane in type 2 diabetes are limited.
5.4 Autism Spectrum Disorder (ASD)
Previous clinical trials of oral sulforaphane demonstrated positive clinical effects on behavior in young men and changes in urinary metabolomics in children with ASD. A 15-week randomized parallel double-blind placebo-controlled clinical trial with 15-week open-label treatment and 6-week no-treatment extensions enrolled 57 children, ages 3–12 years, with ASD over 36 weeks. Twenty-eight were assigned sulforaphane and 29 received placebo. Clinical effects, safety and tolerability, and biomarkers were measured.
For brain disorders, sulforaphane demonstrated symptomatic improvements in autism spectrum disorder and cognitive benefits in schizophrenia, but lacked robust biomarker integration.
In a human longitudinal study, the average verbal or non-verbal communication scores of the sulforaphane group changed significantly at the 12-week endpoint. Sulforaphane was safe and no serious side effects were observed.
Evidence strength: Preliminary. Multiple small RCTs and open-label trials have been conducted at Johns Hopkins and other centers, showing behavioral improvements. Sample sizes remain small, and larger, more definitive trials are ongoing. Approximately 50% of completed trials remain unpublished, raising concerns about publication bias, and limited sample sizes and inconsistent outcomes underscore the need for more extensive, stratified trials.
5.5 Neuroprotection — Neurodegeneration and Brain Disorders
The protective effects of sulforaphane on brain health have been considerably studied; studies have extended to several neurological diseases including Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorder, and schizophrenia.
Sulforaphane has been shown to exert neuroprotective effects through the activation of the Nrf2 pathway, the modulation of neuroinflammation, and epigenetic mechanisms. In studies involving models of amyloid precursor protein expression, sulforaphane was observed to induce Nrf2 expression by reducing DNA methylation levels at the Nrf2 promoter. The activation of the Nrf2-ARE pathway, subsequently leading to the upregulation of key downstream elements such as NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, and glutathione peroxidase 1, plays a pivotal role in countering oxidative stress.
The increase in pre-clinical evidence consistently suggests that sulforaphane has a multifaceted neuroprotective effect on Alzheimer's disease pathophysiology, though the anti-AD-like evidence of sulforaphane is largely seen in cells and animals.
Evidence strength: Largely preclinical (in vitro and animal models). Human clinical evidence specifically for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions remains very limited.
5.6 Helicobacter pylori Infection and Gastric Health
A sulforaphane-rich broccoli sprout diet was found to reduce colonization and attenuate gastritis in people infected with Helicobacter pylori. A human study (Yanaka et al., 2009, referenced in multiple reviews) evaluated the efficacy of broccoli sprouts in reducing H. pylori infection. The findings suggest that sulforaphane may have a direct antibacterial effect on H. pylori, resulting in reduced gastritis, as well as an indirect effect by increasing the cytoprotective phase 2 response.
Evidence strength: Preliminary. A small number of human studies show reduction in gastric colonization and inflammation, but large RCTs are lacking.
5.7 Respiratory and Pulmonary Health
Sulforaphane had minimal impact on respiratory diseases but showed supportive roles in allergic rhinitis therapy. Prior clinical work has also explored sulforaphane in individuals with asthma: a study referenced in the clinical trials literature (Brown et al., 2015) found that sulforaphane improves the bronchoprotective response in asthmatics through Nrf2-mediated gene pathways.
Evidence strength: Limited and mixed in human populations. Most respiratory evidence derives from mechanistic or small pilot studies.
5.8 Cardiovascular and Metabolic Protection
The liver and nervous system have been the target organs attracting the most attention due to the key role of oxidative stress in liver and neurodegenerative diseases. However, protective activities have also been demonstrated in the lungs, heart, immune system, kidneys, and endocrine system. Preclinical evidence supports an active role of sulforaphane in activating NRF2 or effectively modulating AMP-activated protein kinase (AMPK) to protect against diabetic complications, including diabetic cardiomyopathy, diabetic neuropathy, diabetic nephropathy, non-alcoholic fatty liver disease, and skeletal muscle insulin resistance.
Evidence strength: Largely preclinical. Human evidence is indirect, arising mainly from dietary intervention studies with broccoli-rich foods rather than isolated sulforaphane.
5.9 Gastrointestinal Motility
It has been reported that daily intake of a sulforaphane-rich broccoli sprout diet for 4 weeks improved defecation bowel habits in human subjects.
Evidence strength: Very preliminary; based on limited human observations.
6. Body Systems and Health Areas Associated With Sulforaphane
- Oncology/Chemoprevention: Multiple cancer types investigated in clinical trials, including prostate, breast, pancreatic, and lung cancers. Sulforaphane has been under clinical trials for prostate cancer, breast cancer, and lung cancer, among others.
- Nervous System/Neuroprotection: Neurological diseases studied include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, autism spectrum disorder, and schizophrenia.
- Metabolic/Endocrine: Glucose homeostasis, insulin resistance, and type 2 diabetes complications.
- Hepatic: Liver protection via Nrf2 activation and anti-inflammatory effects.
- Cardiovascular: Cardioprotection in diabetic cardiomyopathy models via AMPK-NRF2.
- Gastrointestinal: H. pylori suppression, gastric mucosal cytoprotection, bowel motility.
- Respiratory: Allergic rhinitis, asthma bronchoprotection.
- Detoxification/Xenobiotic Metabolism: Enhanced urinary excretion of carcinogens (benzene, acrolein) and aflatoxin-DNA adducts in human trials.
- Ophthalmic: Sulforaphane has been studied in ophthalmic diseases such as age-related macular degeneration (AMD), diabetic retinopathy, cataract, and retinal degeneration.
7. Dosage Forms and Doses Reported in Studies
Based on current clinical evidence, doses reported in studies include approximately 20–40 mg/day (~100–200 µmol sulforaphane) from dietary sources or supplements for general health benefits, and 100–200 µmol/day for up to 20 weeks as supported by cancer prevention and adjunct therapy clinical trials. Sulforaphane demonstrates a strong safety profile at moderate doses, with long-term supplementation (30–200 µmol/day) being well tolerated in clinical studies.
Specific doses from notable human studies include:
- In the Qidong, China air pollution trial: a broccoli sprout-derived beverage providing daily doses of 600 micromole glucoraphanin and 40 micromole sulforaphane for 12 weeks.
- In a breast tissue bioavailability study: 8 women undergoing mammoplasty consumed a preparation containing 200 µmol of sulforaphane approximately 50 minutes prior to surgery.
- In a Phase I broccoli sprout preparation safety study, 12 healthy human volunteers received doses of broccoli sprout preparation every 8 hours for 7 days (total 21 doses). Doses used across cohorts were 25 µmol glucosinolates, 100 µmol glucosinolates, and 25 µmol isothiocyanates; thus subjects received 75–300 µmol glucosinolates daily, equivalent to 12–50 g of fresh broccoli seeds, or 75 µmol isothiocyanate. No clinical adverse events were reported.
- In a schizophrenia bioavailability study: 7 Avmacol® tablets orally, each containing 15 mg of glucoraphanin, for an expected sulforaphane dose averaging 100–150 µmol.
- In a pediatric ASD pilot: children with ASD received 2.2 micromoles/kg sulforaphane daily for 14 days.
- An oral intake of 68 grams of broccoli sprouts has been described as providing a non-toxic dose of 100 mg of sulforaphane that has proven therapeutic in cancer models.
The doses used in the majority of animal experiments have exceeded the maximum dosage of sulforaphane administered to humans. Thus, comprehensive dose–response studies are necessary to provide crucial information for establishing sensible sulforaphane dose regimens to improve safety and efficiency in clinical translation.
8. Safety Considerations and Drug Interactions
8.1 General Safety Profile
Broccoli sprouts are widely consumed as a food all over the world without any reported adverse effects. Research studies performed in humans have not demonstrated any significant adverse effects of administration of sulforaphane or sulforaphane-enriched dietary items such as broccoli sprouts. Increasing evidence supports the view that sulforaphane is considered to be of low toxicity.
However, the safety of sulforaphane must be assessed due to its potential negative effects, including chromosomal damage, skin diseases, tumor progression, and overall toxicity, as suggested by in silico studies. According to results from limited animal research, for long-term use of sulforaphane, it is crucial to carefully consider factors like dosage, timing, and duration. More research, including in vitro and in vivo studies, is needed to confirm potential adverse effects and to establish safe levels of sulforaphane exposure.
Sulforaphane has potential clinical applications as a chemoprotective agent. Nevertheless, more studies are necessary to set the safe doses of sulforaphane in humans.
8.2 Gastrointestinal Side Effects
Some potential adverse effects of sulforaphane supplementation may include gastrointestinal discomforts such as nausea, vomiting, and diarrhea. These effects are primarily reported at higher doses and in supplement form rather than from dietary consumption of cruciferous vegetables.
8.3 Thyroid Function
Sulforaphane has also been found to have goitrogenic effects, which can interfere with thyroid function and may exacerbate thyroid disorders in some individuals. The safety of sulforaphane supplements during pregnancy and breastfeeding is not well established.
8.4 Drug–Drug Interactions via CYP Enzyme Modulation
Sulforaphane is extensively metabolized and can compete with other substrates of Phase I, II, and III enzymes and transporters. It has an unusually high potency as an inducer of phase II enzymes and regulates the expression and function of different cytochrome P-450 genes.
Sulforaphane can significantly down-regulate cytochrome P450 3A4 (CYP3A4) expression in human primary hepatocytes. CYP3A4 is responsible for the hepatic and intestinal metabolism of numerous protoxicants, pharmaceutical compounds, and endogenous sterols.
There is evidence from animal studies and in vitro studies suggesting that sulforaphane and/or its metabolites can inhibit expression of CYP 1A2, 3A4, and 2D6, which could be a potential source of drug–drug interactions if the participant is taking medications that are substrates of these enzymes. The risk of possible drug–drug interactions is not well-established in humans.
Sulforaphane has been shown to modulate cytochrome P450 (CYP450) activity, especially CYP1A2, CYP2E1, and CYP3A4, which are involved in metabolizing a wide range of drugs including warfarin, clopidogrel, benzodiazepines, and some statins. Sulforaphane may affect drug metabolism by inhibiting CYP450 enzymes, potentially altering plasma drug concentrations.
8.5 Interaction with Chemotherapy
In cancer treatment, sulforaphane has demonstrated the ability to selectively induce cell death in cancer cells, inhibit histone deacetylase, and sensitize cancer cells to chemotherapy. However, the interaction of sulforaphane with specific chemotherapeutic agents requires careful, case-by-case clinical consideration, as the same enzyme-modulating properties that may sensitize tumors could theoretically alter the pharmacokinetics of co-administered cytotoxic drugs.
8.6 Limitations of the Current Evidence
Approximately 50% of completed sulforaphane trials remain unpublished, raising concerns about publication bias. While published results highlight sulforaphane's therapeutic potential, limited sample sizes and inconsistent outcomes underscore the need for more extensive, stratified trials. The majority of mechanistic findings derive from cell and animal studies, and clinical translation is at an early stage for most indications outside of environmental detoxification.
References
Volver